Shares of Aurobindo Pharma Ltd soared roughly 4% on Wednesday, 6 May, after the company said that the US Food and Drug Administration (USFDA) has classified its Unit-VII facility in Telangana as “Voluntary Action Indicated” (VAI). The factory, which produces oral solid dosage products, is located at the Special Economic Zone (Pharma), TSIIC, Green Industrial…
April 20, 2026April 20, 2026 Shares of Aurobindo Pharma Limited touched a 52-week high of Rs 1,396.60 on the BSE on 20 April, rising 0.79% from the previous close of Rs 1,385.65, after the company secured two product approvals from the U.S. Food and Drug Administration. The pharma firm…
April 17, 2026April 17, 2026 Shares of Aurobindo Pharma Limited edged up on 17 April after the company secured final approval from the US Food and Drug Administration for Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL. At 11:47 am, the stock was trading up…
March 20, 2026March 20, 2026 Shares of Aurobindo Pharma Ltd soared 3% on 20 March after the company announced that its wholly owned subsidiary, Apitoria Pharma Pvt Ltd, has acquired a ‘Voluntary Action Indicated’ (VAI) classification from the US Food and Drug Administration (USFDA) for its Unit-V production facility….
CuraTeQ Biologics, the wholly owned step-down subsidiary of Aurobindo Pharma Ltd, on 2 July announced that it has obtained marketing authorisation from the European Commission for its trastuzumab biosimilar, Dazublys. This approval follows the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issuing a positive opinion in April 2025, recommending Dazublys…
August 16, 2024August 16, 2024 Shares of Aurobindo Pharma Ltd. dropped 6% after touching a day’s high of Rs 1,527 on 16th August, following the company’s disclosure that its Eugia Pharma Specialties Ltd. Unit-III received a warning letter from the USFDA. The USFDA issues warning letters to companies to…
Shares of Aurobindo Pharma Ltd were trading 3% higher on 3 June after the company’s wholly-owned subsidiary, TheraNym Biologics, signed a master service agreement for contract manufacturing of biologicals with Merck Sharpe & Dohme Singapore. As a part of this agreement, TheraNym will produce biologics for both domestic and international markets on behalf of Merck…